Efficacy and Safety of All Monoclonal Antibodies in Moderate‐to‐Severe Atopic Dermatitis: A Systematic Review and Network Meta‐Analysis

ABSTRACT Objective The aim of this study was to compare the efficacy and safety of monoclonal antibodies (mAb) for moderate‐to‐severe atopic dermatitis (AD). Methods The randomized controlled trials (RCTs) of monoclonal antibodies in the treatment of moderate‐to‐severe AD were searched in the database of PubMed, Embase, Web of Science and Cochrane Library, up to November 2024. The control group included placebo. The efficacy indicators were the percentage of patients achieving 50%, 75%, 90% improvement in Eczema Area and Severity Index score (EASI‐50, EASI‐75, EASI‐90) and the percentage of patients with an Investigator Global Assessment (IGA) Score of 0 or 1 from baseline until the time of efficacy observation, and the percent change in Pruritus Numerical Rating Scale (NRS), EASI score, SCORing Atopic Dermatitis (SCORAD), and change in Percent Body Surface Area (BSA), Dermatology Life Quality Index (DLQI). The statistical analysis was performed by Stata14 and RevMan5.4. Data processing, network evidence plots, surface under the cumulative ranking curve (SUCRA) ranking, league plots and funnel plots were generated. Risk ratio (RR) and 95% confidence interval (95% CI) were used as effect sizes to analyze binary categorical variables. Results This study included 32 RCTs with 7588 patients. Spesolimab, Rademikibart, Dupilumab, Amlitelimab were more effective than placebo in EASI‐50 (RRs ranging between 1.31 and 22.65), EASI‐75(RRs ranging between 1.51 and 36.58), EASI‐90(RRs ranging between 3.72 and 5.49), and the percentage of patients in IGA score of 0 or 1 (RRs ranging between 1.78 and 13.36). Dupilumab showed relatively good efficacy according to SUCRA ranking on percent change in NRS, EASI, SCORAD. Dupilumab exhibited a lower incidence of serious adverse events than placebo, and the difference was statistically significant (RR = 0.43, 95% CI 0.30–0.63). Other safety analysis results showed no statistical difference. Conclusions Through the analysis of the primary efficacy indicators, this network meta‐analysis (NMA) study indicated that all monoclonal antibodies performed better than placebo. Based on the results of this study, Spesolimab, Rademikibart, Dupilumab, Amlitelimab were recommended treatment options with relatively good efficacy and safety.